Bioiberica to launch Hialsorb® Intraarticular, a hyaluronic acid injection for the treatment of pain and inflammation associated with osteoarthritis
- Hialsorb Intraarticular restores viscosity and elasticity of synovial fluid
- Its natural, highly pure hyaluronic acid allows for an excellent tolerability
Hyaluronic acid is a biomolecule naturally present in the human body. It is particularly present in the joint’s synovial fluid, which acts as a lubricant for cartilage and ligaments, facilitating movement. Age and overuse caused by certain jobs or sports involving repeated impacts reduces the amount of hyaluronic acid in our joints. This reduction in the level of hyaluronic acid decreases its shock-absorbing ability and results in more wear and tear to the joint, which amounts to increased pain and loss of mobility.
Bioiberica launched Hialsorb® Intraarticular, a hyaluronic acid injection for the treatment of osteoarthritis-associated pain and inflammation. With this new release our biotech company increases their range of specialized products for joint care. Hialsorb® Intraarticular is a single-application injection which restores the viscosity and elasticity of synovial fluid, thus reducing pain and inflammation, increasing mobility and decreasing friction.
Furthermore, the hyaluronic acid of Hialsorb® Intraarticular is of natural origin-it is not mixed with other chemical agents. Through a strict production process, we obtain a highly pure compound which guarantees excellent tolerability by the human body.
Related News
With World Digestive Health Day around, shortly followed by World Allergy Awareness Week (5-11 June), we’re exploring the increasing relevance of a relatively unknown digestive health disorder – histamine intolerance.
New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.